Allon Files CTA to Add Canadian Sites to Phase II Clinical Trial

Allon Files CTA to Add Canadian Sites to Phase II Clinical Trial: "Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that it has filed a Clinical Trial Application (CTA) with Health Canada to gain approval to begin recruiting Canadian patients into its ongoing Phase II human clinical trial evaluating the Company's product AL-208 as a treatment for the mild cognitive impairment that commonly occurs following coronary artery bypass graft (MCI post-CABG) surgery."